Zura Bio presents Phase 2 TibuSURE trial design at SSc World Congress; no data yet

Zura Bio Ltd

Design of Phase 2 TibuSURE trial evaluating tibulizumab (dual IL-17A/BAFF inhibition) in diffuse cutaneous systemic sclerosis accepted for poster presentation.
Trial enrolls ~80 adults, randomized 1:1 tibulizumab versus placebo for 24 weeks, then 28-week open-label extension.
Primary endpoint is change in modified Rodnan Skin Score at Week 24; topline results expected first half 2027.
No clinical efficacy or safety data will be presented; poster covers rationale and study design only.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.